Taken together, prior studies provide the mechanistic and epidemiologic foundation for an oncologic role of PDE5 inhibitors, which our work extends across additional male-predominant cancer sites including prostate, bladder, laryngeal, and esophageal. This evidence concerns the gene PDE5A and cancer.